TY - JOUR
T1 - Aptamer-mediated transcriptional gene silencing of Foxp3 inhibits regulatory T cells and potentiates antitumor response
AU - Manrique-Rincón, Andrea J.
AU - Ruas, Luciana P.
AU - Fogagnolo, Carolinne T.
AU - Brenneman, Randall J.
AU - Berezhnoy, Alexey
AU - Castelucci, Bianca
AU - Consonni, Sílvio R.
AU - Gilboa, Eli
AU - Bajgelman, Marcio C.
N1 - Funding Information:
We thank the Viral Vector lab and the animal facility at LNBio-CNPEM for providing the viral vector preparations and animal care, as well as Eugenia Camargo for assistance with flow cytometry. We also thank the Flow cytometry facility at UNICAMP for assistance with cell-sorting and AMNIS experiments. We thank the hematology core at UNICAMP for cell irradiation for GVAX generation and Michel Vaz de Oliveira for helping with animal experiments. We thank Dr. Glenn Dranoff for kindly providing GM-CSF B16F10 cells, Dr. Kevin Morris for support with the transcriptional gene silencing algorithm, as well as Dr. Andrew Waters for his careful reading and helpful comments on the manuscript. This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) (Grants MCB-2012/13132-0 and MCB-2019/04458-8 and the fellowship AJMR-2013/02041-6 ).
Publisher Copyright:
© 2021 The Authors
PY - 2021/9/3
Y1 - 2021/9/3
N2 - The inhibition of immunosuppressive mechanisms may switch the balance between tolerance and surveillance, leading to an increase in antitumor activity. Regulatory T cells play an important role in the control of immunosuppression, exhibiting the unique property of inhibiting T cell proliferation. These cells migrate to tumor sites or may be generated at the tumor site itself from the conversion of lymphocytes exposed to tumor microenvironment signaling. Because of the high similarity between regulatory T cells and other lymphocytes, the available approaches to inhibit this population are nonspecific and may antagonize antitumor response. In this work we explore a new strategy for inhibition of regulatory T cells based on the use of a chimeric aptamer targeting a marker of immune activation harboring a small antisense RNA molecule for transcriptional gene silencing of Foxp3, which is essential for the control of the immunosuppressive phenotype. The silencing of Foxp3 inhibits the immunosuppressive phenotype of regulatory T cells and potentiates the effect of the GVAX antitumor vaccine in immunocompetent animals challenged with syngeneic tumors. This novel approach highlights an alternative method to antagonize regulatory T cell function to augment antitumor immune responses.
AB - The inhibition of immunosuppressive mechanisms may switch the balance between tolerance and surveillance, leading to an increase in antitumor activity. Regulatory T cells play an important role in the control of immunosuppression, exhibiting the unique property of inhibiting T cell proliferation. These cells migrate to tumor sites or may be generated at the tumor site itself from the conversion of lymphocytes exposed to tumor microenvironment signaling. Because of the high similarity between regulatory T cells and other lymphocytes, the available approaches to inhibit this population are nonspecific and may antagonize antitumor response. In this work we explore a new strategy for inhibition of regulatory T cells based on the use of a chimeric aptamer targeting a marker of immune activation harboring a small antisense RNA molecule for transcriptional gene silencing of Foxp3, which is essential for the control of the immunosuppressive phenotype. The silencing of Foxp3 inhibits the immunosuppressive phenotype of regulatory T cells and potentiates the effect of the GVAX antitumor vaccine in immunocompetent animals challenged with syngeneic tumors. This novel approach highlights an alternative method to antagonize regulatory T cell function to augment antitumor immune responses.
KW - FoxP3
KW - Treg
KW - aptamer
KW - immunotherapy
KW - transcriptional gene silencing
UR - http://www.scopus.com/inward/record.url?scp=85113239957&partnerID=8YFLogxK
U2 - 10.1016/j.omtn.2021.05.005
DO - 10.1016/j.omtn.2021.05.005
M3 - Article
C2 - 34457999
AN - SCOPUS:85113239957
SN - 2162-2531
VL - 25
SP - 143
EP - 151
JO - Molecular Therapy - Nucleic Acids
JF - Molecular Therapy - Nucleic Acids
ER -